Understanding Ebola: the 2014 Epidemic Jolie Kaner1,2 and Sarah Schaack2*

Total Page:16

File Type:pdf, Size:1020Kb

Understanding Ebola: the 2014 Epidemic Jolie Kaner1,2 and Sarah Schaack2* Kaner and Schaack Globalization and Health (2016) 12:53 DOI 10.1186/s12992-016-0194-4 REVIEW Open Access Understanding Ebola: the 2014 epidemic Jolie Kaner1,2 and Sarah Schaack2* Abstract Near the end of 2013, an outbreak of Zaire ebolavirus (EBOV) began in Guinea, subsequently spreading to neighboring Liberia and Sierra Leone. As this epidemic grew, important public health questions emerged about how and why this outbreak was so different from previous episodes. This review provides a synthetic synopsis of the 2014–15 outbreak, with the aim of understanding its unprecedented spread. We present a summary of the history of previous epidemics, describe the structure and genetics of the ebolavirus, and review our current understanding of viral vectors and the latest treatment practices. We conclude with an analysis of the public health challenges epidemic responders faced and some of the lessons that could be applied to future outbreaks of Ebola or other viruses. Keywords: Ebola, Ebolavirus, 2014 outbreak, Epidemic, Review Abbreviations: BEBOV, Bundibugyo ebolavirus;CIEBOV,Côte d’Ivoire ebolavirus;EBOV,Ebolavirus; EVD, Ebola virus disease or Ebola; Kb, Kilobase; MSF, Médecins Sans Frontières; REBOV, Reston ebolavirus; SEBOV, Sudan ebolavirus;WHO,World Health Organization; ZEBOV, Zaire ebolavirus Background NP (nucleoprotein), VP35 (polymerase cofactor), VP40 As of April 13th, 2016 there have been 28,652 total cases (matrix protein), GP (glycoprotein), VP30 (transcrip- of Ebola virus disease (EVD; or more generally Ebola) in tion activator), VP24 (secondary matrix protein), and the 2014–2015 West African epidemic [1]. Of these, RNA-dependent RNA polymerase [6]. There are currently 11,325 cases (40 %) were fatal [1]. During this epidemic, five recognized species of ebolavirus: Zaire ebolavirus the vast majority of cases were concentrated in Guinea, (ZEBOV), Sudan ebolavirus (SEBOV), Reston ebolavirus Liberia, and Sierra Leone, with a handful of cases (REBOV) (non-pathogenic to humans), Côte d’Ivoire ebo- imported to countries around the world [1]. This was lavirus (CIEBOV) also known as Tai Forest ebolavirus and the first outbreak of Ebola in West Africa, and the most Bundibugyo ebolavirus (BEBOV) [5, 7]. significant Ebola epidemic that has occurred worldwide Estimates of the rate of nucleotide substitution for since the virus was first described [2]. Here, we review filoviruses suggest that these viruses have substitution the current understanding of biology and genetics of rates approximately 100× times lower than other RNA the virus, the past and current epidemiology, and the viruses (e. g. retroviruses and influenza A) [8]. Based on public health response to the 2014–15 Ebola outbreak. these substitution rates, studies have concluded that ebolavirus and marburgvirus, a closely related filovirus that is also pathogenic in humans, likely diverged from Ebolavirus genetics each other several thousand years ago and that the The ebolavirus is a member of the family filoviridae, different species of ebolavirus diverged from each other which is composed of single-stranded negative-sense within the last ~1000 years ago [8, 9]. Genetic analysis enveloped RNA viruses [3]. These filamentous viruses of strains from the 2014–2015 West African Ebola are ~19 kilobases (kb) in length (800–1100 nanometers epidemic have been hindered, in part, due to the limited [nm] long and 80 nm in diameter) [4]. The ebolavirus understanding of the biology of this virus and further genome contains seven genes (3′ NP VP35 VP40 GP exacerbated by delays in sample export, bad record VP30 VP24 L 5′ [5]) encoding a number of proteins: keeping, and a small number of trained specialists * Correspondence: [email protected] [10, 11]. Gire et al. [12] analyzed 81 EBOV sequences, 2Department of Biology, Reed College, 3203 SE Woodstock Blvd, Portland, OR 78 newly derived from patients in Sierra Leone and 3 97202, USA previously published Guinean sequences, and found Full list of author information is available at the end of the article © 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. Kaner and Schaack Globalization and Health (2016) 12:53 Page 2 of 7 341 fixed substitutions and 55 single-nucleotide poly- many locations, suggesting that infection (and survival) morphisms. They concluded that the substitution rate is frequent [4]. Retrospective analysis shows that wildlife during this outbreak is roughly twice as high as those deaths (non-human primates and antelope) tend to pre- previously reported. Other studies show contrasting cede human infections, which this could have important results, however; e.g. Spielman et al. [13] and Hoenen surveillance implications in terms of preventing future et al. [14] analyzed sequences from the recent epidemic outbreaks [20]. In addition, population declines in − − and reported a mutation rates of 9.6 × 10 4 and 1.3 × 10 3 apes have also been chronologically linked to human substitutions per site per year, respectively, which are Ebola outbreaks and a number of molecular studies similar to those reported during past outbreaks. have linked primate ebolavirus cases to human Ebola A more recent study by Carroll et al. [15] used 197 outbreaks [4]. new viral sequences in addition to publicly-available Although two types of transmission (animal-to-human sequences to trace the evolution of the viral genome and human-to-human) have been observed, nosocomial throughout the epidemic. They estimated the date of the transmission has played a key role in the spread of most recent common ancestor of the sampled viruses to Ebola. Transmission from animals has taken place via be between December 12th, 2013 and February 18th, the handling and butchering of infected animals, inc- 2014, which is supported by epidemiological evidence luding bats, non-human primates and duikers (a small that places the index case in late December 2013 [15]. forest antelope) [21]. Healthcare workers are especially Another recent study by Simon-Loriere et al. [16] ana- at risk for exposure to Ebola because they are more lyzed 85 new sequences from Guinean patients along likely to come into contact with contaminated bodily with 110 publicly-available EBOV sequences from this fluids [22]. The traditional funeral and burial practices in − outbreak and reported a mutation rate of 0.87 × 10 3 to West Africa involve washing the body by hand before − 0.91 × 10 3 substitutions per site per year. They point burial and paying respect to the dead through physical out that evolutionary rates in RNA viruses can be strongly contact which are both exceptionally high-risk activities time-dependent, with higher rates observed over short with regard to the spread of Ebola [23]. The incubation time spans than long ones [16]. This may explain why period for Ebola can range from two to 21 days, but is certain estimates of mutation rates during this recent usually one to two weeks [24]. There is no evidence that epidemic have been higher than expected. Ebola is contagious during the incubation period, while infected individuals are still asymptomatic [25]. The Past Ebola outbreaks World Health Organization (WHO) will only declare an Since the first outbreak 40 years ago, EVD outbreaks Ebola outbreak over once 42 days (two incubation pe- have been rare, small and localized. The first recorded riods) have passed with no new infections reported [26]. outbreak of EVD took place in Zaire (now the De- Interrupting Ebola transmission requires rapid identifi- mocratic Republic of the Congo) in 1976, close to the cation of cases, contact tracing, and monitoring of Yambuku Catholic Mission Hospital located near the people identified as high risk [22, 27]. Based on a retro- Ebola River Valley [7]. At the same time, a separate out- spective study of the 1995 outbreak in Kikwit DRC, the break of EVD occurred near Maridi in West Equatoria greatest risk factor for secondary household transmission Region in Sudan [7]. Prior to 2014, the largest recorded of Ebola is direct contact with someone who has clinic- outbreak of Ebola (SEBOV in this case) took place in ally apparent illness [28]. This risk increases if there is Uganda from October 2000 to January 2001, with 425 contact with bodily fluids or the infected person is in the cases and 225 deaths [17, 18]. late stages of the disease. Direct contact was determined After the discovery of the virus, a large variety of to be necessary, but not sufficient, for transmission [28]. organisms were screened as possible Ebola reservoirs. To date, the only comprehensive analysis of viral excre- Bats both efficiently replicate the virus and survive infec- tion and environmental contamination from Ebola found tion, which made them standout as candidate reservoirs viral particles are present in blood, breast milk, saliva, [4]. Despite this initial evidence, the first direct evidence semen, feces, and tears [29]. A review of relevant lite- that bats are reservoir hosts of ebolavirus was reported rature by Thorsen et al. [30] found that the longest re- in a field study in 2005, almost 30 years after the discov- corded persistence of EBOV in semen is 284 days. While ery of the virus [19]. Immunoglobulin G (IgG) specific viral RNA was isolated from this sample, it is not known for ebolavirus was found in serum from bats of three if the viral particles were still infectious. Viable Ebola different species of fruit bat (Hypsignathus monstrosus, virus has been found in semen 82 days post-infection Epomps franqueti, and Myonycteris torquata) and phylo- and may be present much longer than this [30].
Recommended publications
  • Eradicating Ebola: Lessons Learned and Medical Advancements Hearing
    ERADICATING EBOLA: LESSONS LEARNED AND MEDICAL ADVANCEMENTS HEARING BEFORE THE SUBCOMMITTEE ON AFRICA, GLOBAL HEALTH, GLOBAL HUMAN RIGHTS, AND INTERNATIONAL ORGANIZATIONS OF THE COMMITTEE ON FOREIGN AFFAIRS HOUSE OF REPRESENTATIVES ONE HUNDRED SIXTEENTH CONGRESS FIRST SESSION JUNE 4, 2019 Serial No. 116–44 Printed for the use of the Committee on Foreign Affairs ( Available: http://www.foreignaffairs.house.gov/, http://docs.house.gov, or http://www.govinfo.gov U.S. GOVERNMENT PUBLISHING OFFICE 36–558PDF WASHINGTON : 2019 COMMITTEE ON FOREIGN AFFAIRS ELIOT L. ENGEL, New York, Chairman BRAD SHERMAN, California MICHAEL T. MCCAUL, Texas, Ranking GREGORY W. MEEKS, New York Member ALBIO SIRES, New Jersey CHRISTOPHER H. SMITH, New Jersey GERALD E. CONNOLLY, Virginia STEVE CHABOT, Ohio THEODORE E. DEUTCH, Florida JOE WILSON, South Carolina KAREN BASS, California SCOTT PERRY, Pennsylvania WILLIAM KEATING, Massachusetts TED S. YOHO, Florida DAVID CICILLINE, Rhode Island ADAM KINZINGER, Illinois AMI BERA, California LEE ZELDIN, New York JOAQUIN CASTRO, Texas JIM SENSENBRENNER, Wisconsin DINA TITUS, Nevada ANN WAGNER, Missouri ADRIANO ESPAILLAT, New York BRIAN MAST, Florida TED LIEU, California FRANCIS ROONEY, Florida SUSAN WILD, Pennsylvania BRIAN FITZPATRICK, Pennsylvania DEAN PHILLIPS, Minnesota JOHN CURTIS, Utah ILHAN OMAR, Minnesota KEN BUCK, Colorado COLIN ALLRED, Texas RON WRIGHT, Texas ANDY LEVIN, Michigan GUY RESCHENTHALER, Pennsylvania ABIGAIL SPANBERGER, Virginia TIM BURCHETT, Tennessee CHRISSY HOULAHAN, Pennsylvania GREG PENCE, Indiana
    [Show full text]
  • Ebola Hemorrhagic Fever: Properties of the Pathogen and Development of Vaccines and Chemotherapeutic Agents O
    ISSN 00268933, Molecular Biology, 2015, Vol. 49, No. 4, pp. 480–493. © Pleiades Publishing, Inc., 2015. Original Russian Text © O.I. Kiselev, A.V. Vasin, M.P. Shevyryova, E.G. Deeva, K.V. Sivak, V.V. Egorov, V.B. Tsvetkov, A.Yu. Egorov, E.A. RomanovskayaRomanko, L.A. Stepanova, A.B. Komissarov, L.M. Tsybalova, G.M. Ignatjev, 2015, published in Molekulyarnaya Biologiya, 2015, Vol. 49, No. 4, pp. 541–554. REVIEWS UDC 578.2,578.76 Ebola Hemorrhagic Fever: Properties of the Pathogen and Development of Vaccines and Chemotherapeutic Agents O. I. Kiseleva, A. V. Vasina, b, M. P. Shevyryovac, E. G. Deevaa, K. V. Sivaka, V. V. Egorova, V. B. Tsvetkova, d, A. Yu. Egorova, E. A. RomanovskayaRomankoa, L. A. Stepanovaa, A. B. Komissarova, L. M. Tsybalovaa, and G. M. Ignatjeva a Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg, 197376 Russia; email: [email protected] b St. Petersburg State Polytechnic University, St. Petersburg, 195251 Russia c Ministry of Health of the Russian Federation, Moscow, 127994 Russia d Topchiev Institute of Petrochemical Synthesis, Moscow, 119991 Russia Received December 29, 2014; in final form, January 16, 2015 Abstract—Ebola hemorrhagic fever (EHF) epidemic currently ongoing in West Africa is not the first among numerous epidemics in the continent. Yet it seems to be the worst EHF epidemic outbreak caused by Ebola virus Zaire since 1976 as regards its extremely large scale and rapid spread in the population. Experiments to study the agent have continued for more than 20 years. The EHF virus has a relatively simple genome with seven genes and additional reading frame resulting from RNA editing.
    [Show full text]
  • To Ebola Reston
    WHO/HSE/EPR/2009.2 WHO experts consultation on Ebola Reston pathogenicity in humans Geneva, Switzerland 1 April 2009 EPIDEMIC AND PANDEMIC ALERT AND RESPONSE WHO experts consultation on Ebola Reston pathogenicity in humans Geneva, Switzerland 1 April 2009 © World Health Organization 2009 All rights reserved. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distin- guished by initial capital letters. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the policies of the World Health Organization.
    [Show full text]
  • Understanding Ebola
    Understanding Ebola With the arrival of Ebola in the United States, it's very easy to develop fears that the outbreak that has occurred in Africa will suddenly take shape in your state and local community. It's important to remember that unless you come in direct contact with someone who is infected with the disease, you and your family will remain safe. State and government agencies have been making preparations to address isolated cases of infection and stop the spread of the disease as soon as it has been positively identified. Every day, the Centers of Disease Control and Prevention (CDC) is monitoring developments, testing for suspected cases and safeguarding our lives with updates on events and the distribution of educational resources. Learning more about Ebola and understanding how it's contracted and spread will help you put aside irrational concerns and control any fears you might have about Ebola severely impacting your life. Use the resources below to help keep yourself calm and focused during this unfortunate time. Ebola Hemorrhagic Fever Ebola hemorrhagic fever (Ebola HF) is one of numerous Viral Hemorrhagic Fevers. It is a severe, often fatal disease in humans and nonhuman primates (such as monkeys, gorillas, and chimpanzees). Ebola HF is caused by infection with a virus of the family Filoviridae, genus Ebolavirus. When infection occurs, symptoms usually begin abruptly. The first Ebolavirus species was discovered in 1976 in what is now the Democratic Republic of the Congo near the Ebola River. Since then, outbreaks have appeared sporadically. There are five identified subspecies of Ebolavirus.
    [Show full text]
  • Overview of Candidate Ebola Vaccines As of August 19, 2019
    Ebola vaccines – Background paper for SAGE deliberations Overview of candidate Ebola vaccines as of August 19, 2019 Nine candidate Ebola vaccines have undergone or are currently undergoing clinical evaluation at different trial phases. Three vaccines were licensed, three vaccines have completed or are in trials up to Phase 1 phase, two vaccines up to or in Phase 2 stage, and one vaccine has completed Phase 3 stage. Type of Developer Strain(s) a. Current stage of clinical Proposed Proposed Proposed target Current storage Current formulation Number of clinical Forecasted production candidate aimed to evaluation vaccination indication population for the specifications* and presentation research grade does capacity vaccine protect schedule label indication available against b. Number of subjects with data (doses per vial) analysed to date c. Regulatory status PROPOSED INDICATION: REACTIVE USE DURING OUTBREAKS Licensed in country of origin Ad5-EBOV CanSino Biologics Zaire a. Phase 1 in China and Phase 2 in 1 dose Reactive 18 to 60 years +2°C to +8°C for 12 Final Formulation: 20,000 doses Can produce 150 000 (monovalent)1 Inc. & Beijing ebolavirus Sierra Leone months Lyophilized doses per year and Institute of (Makona) b. >681 people enrolled potentially scale-up to 500 Biotechnology, c. Licensed obtained from CFDA in 000 doses/year. China October 2017 to use under national Presentation: reserves by National Medical Single dose vial + Products Administration (NMPA), diluent China in the event of Ebola outbreak Submitted to WHO for Emergency Use Assessment and Listing (EUAL) in July 2018. Granted Breakthrough Therapy Designation by the US FDA and PRIME status by the European Medicines Agency (EMA) since 2016 rVSVΔG- Merck, USA Monovalent a.
    [Show full text]
  • Ebola Virus Disease October 2014 • $12.00 US
    SPECIAL DIGITAL ISSUE: Ebola Virus Disease October 2014 • $12.00 US EBOLA VIRUS DISEASE A Primer for Infection Preventionists Ebola Virus Disease: A Primer for Infection Preventionists By Kelly M. Pyrek ccording to the Centers for Disease Control and Prevention (CDC), Ebola — previously known as AEbola hemorrhagic fever — is a rare and deadly disease caused by infection with one of the Ebola virus strains. Ebola can cause disease in humans and non- human primates. Ebola is caused by infection with a virus of the family Filoviridae, genus Ebolavirus. There Ebola, previously known are five identified Ebola virus species, four of which are known to cause disease in humans: Ebola virus as Ebola hemorrhagic (Zaire ebolavirus); Sudan virus (Sudan ebolavirus); fever, is a rare and Taï Forest virus (Taï Forest ebolavirus, formerly Côte d’Ivoire ebolavirus); and Bundibugyo virus (Bundibugyo deadly disease caused ebolavirus). The fifth, Reston virus (Reston ebolavirus), by infection with one of has caused disease in non-human primates, but not in humans. the Ebola virus strains. Ebola was first discovered in 1976 near the Ebola River in what is now the Democratic Republic of the Congo. Since then, outbreaks have appeared sporadically in Africa. The natural reservoir host of Ebola virus remains unknown; however, on the basis of evidence and the nature of similar viruses, researchers believe that the virus is animal-borne and that bats are the most likely reservoir. Four of the five virus strains occur in an animal host native to Africa. INFECTION CONTROL TODAY Ebola Virus Disease www.infectioncontroltoday.com 3 The Outbreak Situation at Home and Abroad: An Update As of Oct.
    [Show full text]
  • Ebola Virus Disease Outbreak in Equateur Province, Democratic Republic of Congo, First Update
    RAPID RISK ASSESSMENT Ebola virus disease outbreak in Equateur Province, Democratic Republic of the Congo First update, 25 May 2018 Main conclusions and options for response This is the ninth Ebola virus disease (EVD) outbreak in the Democratic Republic of the Congo (DRC) since the discovery of the virus in 1976. From 4 April until 20 May 2018, 49 cases and 26 deaths have been recorded: of which 22 are confirmed, 21 are probable and six are suspected cases. Cases have been reported from the Bikoro health zone (n=29; 10 confirmed and 19 probable), the Iboko health zone (n=16; eight confirmed, two probable and six suspected) and the Wangata health zone (n=4; all confirmed) [1]. The current outbreak is taking place in health zones neighbouring the Congo River, which is an important pathway of trade and travel. In addition, four confirmed EVD cases have been reported in the health zone of Wangata within the port city of Mbandaka which has a population of 1.2 million people. These factors have raised concerns about an increased probability of the spread of the disease at the national level. The identification of EVD cases in the urban area of Mbandaka city and around Tumba Lake both connected to the Congo River increases the risk of regional spread to other provinces of DRC and neighbouring countries (namely Republic of the Congo and the Central African Republic). ECDC is closely monitoring this outbreak in liaison with the Ministry of Health in DRC, WHO and other partners, and will re- evaluate the risk for EU/EEA citizens if necessary according to epidemiological findings.
    [Show full text]
  • Risk Assessment and Risk Mitigation Review(S)
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 761169Orig1s000 RISK ASSESSMENT and RISK MITIGATION REVIEW(S) Division of Risk Management (DRM) Office of Medication Error Prevention and Risk Management (OMEPRM) Office of Surveillance and Epidemiology (OSE) Center for Drug Evaluation and Research (CDER) Application Type BLA Application Number 761169 PDUFA Goal Date October 25, 2020 OSE RCM # 2020-264 Reviewer Name(s) Elizabeth Everhart, MSN, RN, ACNP Team Leader Naomi Boston, PharmD Acting Deputy Division Doris Auth, PharmD Director Review Completion Date August 10, 2020; date entered into DARRTS, August 20, 2020 Subject Evaluation of Need for a REMS Established Name atoltivimab – odesivimab – maftivimab (REGN-EB3) Trade Name Inmazeb Name of Applicant Regeneron Pharmaceuticals, Inc. Therapeutic Class Human IgG monoclonal antibody Formulation Solution for infusion Dosing Regimen 50 mg of each mAb/kg (3mL/kg) IV (b) (4) × 1 1 Reference ID: 4659652 Table of Contents EXECUTIVE SUMMARY ............................................................................................................................................................3 1 Introduction........................................................................................................................................................................3 2 Background .........................................................................................................................................................................3 2.1 Product Information..............................................................................................................................................3
    [Show full text]
  • Ebola Virus Disease Outbreak in North Kivu and Ituri Provinces, Democratic Republic of the Congo – Second Update
    RAPID RISK ASSESSMENT Ebola virus disease outbreak in North Kivu and Ituri Provinces, Democratic Republic of the Congo – second update 21 December 2018 Main conclusions As of 16 December 2018, the Ministry of Health of the Democratic Republic of Congo (DRC) has reported 539 Ebola virus disease (EVD) cases, including 48 probable and 491 confirmed cases. This epidemic in the provinces of North Kivu and Ituri is the largest outbreak of EVD recorded in DRC and the second largest worldwide. A total of 315 deaths occurred during the reporting period. As of 16 December 2018, 52 healthcare workers (50 confirmed and two probable) have been reported among the confirmed cases, and of these 17 have died. As of 10 December 2018, the overall case fatality rate was 58%. Since mid-October, an average of around 30 new cases has been reported every week, with 14 health zones reporting confirmed cases in the past 21 days. This trend shows that the outbreak is continuing across geographically dispersed areas. Although the transmission intensity has decreased in Beni, the outbreak is continuing in Butembo city, and new clusters are emerging in the surrounding health zones. A geographical extension of the outbreak (within the country and to neighbouring countries) cannot be excluded as it is unlikely that it will be controlled in the near future. Despite significant achievements, the implementation of response measures remains problematic because of the prolonged humanitarian crisis in North Kivu province, the unstable security situation arising from a complex armed conflict and the mistrust of affected communities in response activities.
    [Show full text]
  • Selection of Functional RNA Aptamers Against Ebola Glycoproteins Shambhavi Shubham Iowa State University
    Iowa State University Capstones, Theses and Graduate Theses and Dissertations Dissertations 2017 Selection of functional RNA aptamers against Ebola glycoproteins Shambhavi Shubham Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/etd Part of the Biochemistry Commons Recommended Citation Shubham, Shambhavi, "Selection of functional RNA aptamers against Ebola glycoproteins" (2017). Graduate Theses and Dissertations. 16528. https://lib.dr.iastate.edu/etd/16528 This Dissertation is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. Selection of functional RNA aptamers against Ebola glycoproteins by Shambhavi Shubham A dissertation submitted to the graduate faculty in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY Major: Molecular Cellular and Developmental Biology Program of Study Committee Marit Nilsen-Hamilton, Major Professor W. Allen Miller Eric Henderson Drena Dobbs Walter Moss Iowa State University Ames, Iowa 2017 Copyright © Shambhavi Shubham 2017. All rights reserved. ii DEDICATION I dedicate this dissertation to my mother Saroj Shrivastava for her constant support and inspiration. iii TABLE OF CONTENTS Page LIST OF FIGURES…………………………………………………………………...v ACKNOWLEDGMENTS……………………………………………………………vii
    [Show full text]
  • Modelling the Daily Risk of Ebola in the Presence and Absence of a Potential Vaccine
    Infectious Disease Modelling 5 (2020) 905e917 Contents lists available at ScienceDirect Infectious Disease Modelling journal homepage: www.keaipublishing.com/idm Modelling the daily risk of Ebola in the presence and absence of a potential vaccine * Stephanie M.C. Abo a, Robert Smith? b, a Department of Applied Mathematics, The University of Waterloo, Waterloo, Canada b Department of Mathematics and Faculty of Medicine, The University of Ottawa, 150 Louis-Pasteur Pvt, Ottawa, ON, K1N6N5, Canada article info abstract Article history: Ebola virus d one of the deadliest viral diseases, with a mortality rate around 90% d Received 1 February 2020 damages the immune system and organs, with symptoms including episodic fever, chills, Received in revised form 4 October 2020 malaise and myalgia. The Recombinant Vesicular Stomatitis Virus-based candidate vaccine Accepted 5 October 2020 (rVSV-ZEBOV) has demonstrated clinical efficacy against Ebola in ring-vaccination clinical Available online 15 October 2020 trials. In order to evaluate the potential effect of this candidate vaccine, we developed risk Handling editor: Dr. J Wu equations for the daily risk of Ebola infection both currently and after vaccination. The risk equations account for the basic transmission probability of Ebola and the lowered risk due Keywords: to various protection protocols: vaccination, hazmat suits, reduced contact with the Ebola virus disease Mathematical model infected living and dead bodies. Parameter space was sampled using Latin Hypercube Risk equations Sampling, a statistical method for generating a near-random sample of parameter values. Latin hypercube sampling We found that at a high transmission rate of Ebola (i.e., if the transmission rate is greater Eradication than 90%), a large fraction of the population must be vaccinated (>80%) to achieve a 50% decrease in the daily risk of infection.
    [Show full text]
  • ACIP-Feb. 2020-Ebola Virus
    National Center for Emerging and Zoonotic Infectious Diseases Background Mary Choi, MD, MPH Viral Special Pathogens Branch Centers for Disease Control and Prevention Advisory Committee on Immunization Practices February 26, 2020 Overview . Ebola virus disease . rVSV ΔG-ZEBOV-GP vaccine . Parameters for WG discussions Background . Ebola virus disease (EVD) in humans is a deadly disease caused by infection with one of 4 viruses within the genus Ebolavirus, family Filoviridae – Ebola virus (species Zaire ebolavirus) – Sudan virus (species Sudan ebolavirus) – Tai Forest virus (species Tai Forest ebolavirus) – Bundibugyo virus (species Bundibugyo ebolavirus) Background . Ebola virus disease (EVD) in humans is a deadly disease caused by infection with one of 4 viruses within the genus Ebolavirus, family Filoviridae – Ebola virus (species Zaire ebolavirus) – Sudan virus (species Sudan ebolavirus) – Tai Forest virus (species Tai Forest ebolavirus) – Bundibugyo virus (species Bundibugyo ebolavirus) Ebola virus (species Zaire ebolavirus) . Responsible for the majority of reported EVD outbreaks*including the 2 largest outbreaks in history – 2014 -2016 West Africa (28,652 cases/11,325 deaths) – Current eastern Democratic Republic of Congo (DRC) . In total, Ebola virus (species Zaire ebolavirus) has infected >31,000 persons and resulted in >12,000 deaths** . Untreated, mortality rates 70-90% . No FDA-approved treatment • * Total of 28 EVD outbreaks reported, 18/28 (64%) due to Ebola virus (species Zaire ebolavirus) • ** Total numbers of infections and deaths due to Ebola virus (species Zaire ebolavirus) but excluding the ongoing 2018 eastern DRC EVD Outbreak Ebola virus reservoir search in Gabon 2002-2003 Hypsignathus monstrosus fruit bat PCR+ 4/21 IgG+ 4/17 Epomops franqueti fruit bat PCR+ 5/117 IgG+ 8/117 Myonycteris torquata fruit bat PCR+ 4/141 IgG+ 4/58 E.
    [Show full text]